Tempest Therapeutics, Inc. · NASDAQ:TPST
Tempest Therapeutics — Investor Presentation (September 2026)
11 slides from Tempest Therapeutics's investor presentation, Sep 15, 2026
Slide 1: Building the Future of in vivo CAR-T
® Building the Future of in vivo CAR-T September 15, 2026
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) concerning Tempest Therapeutics, Inc. (“T
Slide 3: Major Cancers and Autoimmune Diseases are Caused by Dysfunctional Immune Cells
Major Cancers and Autoimmune Diseases are Caused by Dysfunctional Immune Cells The promise of CAR-T: Training T cells to clear diseased immune cells can “reset” the immune system Before Immune Reset After Immune Reset Healthy hematopoietic progenitor cells Healthy hematopoietic progenitor cells in v
Slide 4: Tempest's Lead Program Has Entered Clinical Development
Tempest’s Lead in vivo CAR-T Program Has Entered Clinical Development Lead oncology program in Phase 1; lead autoimmune program planning Phase 1 Q4 2026 IN VIVO CAR-T PROGRAM PAYLOAD INITIAL SETTING STATUS TPST-4903 | CD7-tLVV BCMA × GPRC5D r/r multiple myeloma Phase 1: 6 patients treated TPST-4003
Slide 5: TPST-4003: Dual-Target CAR Architecture Supported by Autologous Clinical Results
TPST-4003: Dual-Target CAR Architecture Supported by Autologous Clinical Results Dual-targeting CARs are designed to avoid antigen escape to enable durable therapeutic response 100% 23.1 mo 100% Complete response among rrMM Median progression-free survival VEGF complete response CAR-T-naïve patients
Slide 6: TPST-4903 Early Data: CAR-T Cell Expansion Similar to Autologous CAR-T
TPST-4903 Early Data: CAR-T Cell Expansion Similar to Autologous CAR-T TPST-4903 generated promising CAR-T cell expansion peaking two weeks after infusion; further dose escalation underway Autologous CAR-T In vivo CAR-T (TPST-2003)1 (TPST-4903)2 1Jiang, H., et. al. “A Prospective Investigator-Initia
Slide 7: Immune Reset Therapies Address Large Cancer and Autoimmune Markets
Immune Reset Therapies Address Large Cancer and Autoimmune Markets Addressable market includes both indications with and without approved CAR-T products Cancer Opportunity Autoimmune Disease Opportunity Indication U.S. Epidemiology Market Size Framing Strategic Implications Indication U.S. Epidemiol
Slide 8: In Vivo CAR-T Is Now a Strategic M&A Category
In Vivo CAR-T Is Now a Strategic M&A Category $1B–$7B announced transactions reflect pharma interest in clinical-stage in vivo CAR-T assets TIMING TRANSACTION ANNOUNCED VALUE STAGE / STRUCTURE Jan 2024 AbbVie × Umoja [1] Up to $1.4B Strategic collaboration Mar 2025 AstraZeneca acquires EsoBiotec [2]
Slide 9: Multiple Near-Term Potential Catalysts Across Two Programs
Multiple Near-Term Potential Catalysts Across Two in vivo CAR-T Programs Clinical and regulatory milestones can validate the immune reset engine NOW Q4 2026 2027 Q4 2027 – Q2 2028 TPST-4903 Phase 1 in rrMM Safety, CAR expression File IND Expand platform to address 6 patients enrolled, + B-cell reset
Slide 10: A Differentiated, Clinical-Data-Backed Investment Case
A Differentiated, Clinical-Data-Backed Investment Case Human validation and multiple potential near-term catalysts converge at a category inflection point THE INVESTMENT THESIS 1 Human experience TPST-4903 in Phase 1/2 • 6 patients • promising early data Human data today. 2 Strategic design Two next
Slide 11: Building the Future of in vivo CAR-T
® Building the Future of in vivo CAR-T September 15, 2026
Tempest Therapeutics — Investor Presentation (September 2026) on 6ix